Nonsynonymous single-nucleotide polymorphisms (nsSNPs) in cytochrome P450 (P450) genes may affect drug metabolism and drug-drug interactions (DDIs), potentially leading to adverse drug reactions. Functional characterization of the nsSNPs in P450 genes is important to help us understand the impact of genetic factors on P450-mediated drug metabolism and DDIs. To evaluate the effects of P450 nsSNPs on the metabolism and inhibition potential of a candidate drug, tanshinol borneol ester (DBZ), we obtained and experimentally validated eight yeast-expressed human P450 isoforms and their nsSNP variants and tested DBZ using these recombinant P450 enzymes. The results suggested that CYP2C8 is the major enzyme responsible for DBZ metabolism. In addition, compared with prototypic CYP2C8, the allelic variant, CYP2C8.3, produced a 54% decrease in the intrinsic clearance of DBZ. The inhibitory potency of DBZ toward CYP3A4 was greater than that toward other P450 isoforms, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Moreover, the inhibitory potency toward three CYP3A4 allelic variants, CYP3A4.2, CYP3A4.12, and CYP3A4.16, was reduced 2-to 10-fold relative to prototype CYP3A4. These results provide useful information for understanding the influence of P450 genetic polymorphisms on DBZ metabolism and may help to design future clinical trials of DBZ. Our results suggest applications for in vitro P450 assays both for basic research in pharmacogenomics and for drug development.
Introduction
Cytochromes P450 (P450s) are the most important drug-metabolizing enzymes because they are responsible for 70 to 80% of all phase I-dependent metabolism of clinically useful drugs. Of the more than 400 single-nucleotide polymorphisms (SNPs) that have been discovered in P450 genes (listed by the Human P450 Allele Nomenclature Committee, www.cypalleles.ki.se), the most important ones are the nonsynonymous SNPs (nsSNPs). nsSNPs lead to the expression of variant P450 enzymes that may possess altered metabolic activities and increase the risk of adverse drug reactions (ADRs) in individuals carrying nsSNPs (Evans and Relling, 1999; Ingelman-Sundberg, 2004) . A well-elucidated clinical example is CYP2C9, in which nsSNPs affect the metabolism of the anticoagulant warfarin. Patients carrying CYP2C9*2 or CYP2C9*3 alleles, which encode altered CYP2C9 proteins (CYP2C9.2 or CYP2C9.3), have higher warfarin plasma concentrations than individuals carrying the prototypic allele, because metabolic clearance of the drug is reduced by the variant CYP2C9 enzymes (Kaminsky and Zhang, 1997; Takahashi et al., 2004; Schwarz et al., 2008) . This result suggests that the warfarin dose needs to be reduced in these patients to prevent bleeding, a severe side effect of this anticoagulant (Higashi et al., 2002; Veenstra et al., 2005; Klein et al., 2009) . Genetic polymorphisms in other P450 isoforms, such as CYP2C19 and CYP2D6, are also known to affect drug efficacy and toxicity, and their clinical consequences have been reviewed extensively (Ingelman-Sundberg et al., 2007; Zhou et al., 2009) .
Another major cause of ADRs is P450-mediated drug-drug interactions (DDIs). When two or more drugs are coadministered, one drug can inhibit a certain P450 isoform that metabolizes the second drug, thus increasing the plasma concentration of the second drug. P450-mediated DDIs commonly occur in clinical practice (Guengerich, 1997; Lin and Lu, 1998; Wienkers and Heath, 2005) , and several drugs have been withdrawn from the market due to ADRs caused by P450-mediated DDIs (Wienkers and Heath, 2005) . Therefore, identifying which P450 isoforms are involved in the metabolism of a given drug and which P450 isoforms are inhibited is crucial for avoiding P450-mediated DDIs [U.S. Food and Drug Administration (FDA), www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072101.pdf] (Bjornsson et al., 2003) .
Pharmacogenomic studies increasingly indicate that P450 nsSNPs can have profound effects on the ability and potency of drugs to inhibit P450s, thus resulting in unexpected DDIs in individuals carrying polymorphic genotypes. It has been reported previously that the inhibitory potency of candesartan (Hanatani et al., 2001) , benzbromarone (Hummel et al., 2005) , and many other drugs (Kumar et al., 2006) toward the CYP2C9.3 variant is altered in vitro compared with that toward the CYP2C9 prototype. Likewise, expression of the CYP2C9*3 allele in patients can alter the degree of drug interaction between flurbiprofen and fluconazole (Kumar et al., 2008) .
P450 genetic polymorphisms and P450-mediated DDIs are both important in the assessment of drug safety and efficacy, and the FDA now requires them to be evaluated for new drug applications (www. fda.gov/ohrms/dockets/98fr/2003d-0497-gdl0002.pdf and www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm072101.pdf). However, the effects of P450 nsSNPs on DDIs are still underappreciated in drug development (Wienkers and Heath, 2005) . In this study, we systematically evaluated the effects of P450 nsSNPs on the metabolism and inhibitory potential of a new drug candidate, tanshinol borneol ester (1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl3-(3,4-dihydroxyphenyl)-2-hydroxy-propanoate; DBZ), which is an experimental drug being developed in our laboratories that exhibits efficacious anti-ischemic effects in animal models.
To evaluate the influences of P450 SNPs, we established a homogenous assay system consisting of eight yeast-expressed human P450 isoforms and their nsSNP variants for the study of DBZ metabolism and inhibition potential. In this system, the potential influences of other factors, such as differences in enzyme preparation, substrate selection, and assay conditions (which may affect P450 activity and drug inhibition) were minimized. Our findings provide useful information for the further development and safety assessment of DBZ.
Materials and Methods
Materials. DBZ was synthesized in our laboratory and verified by highperformance liquid chromatography (HPLC)-mass spectrometry and nuclear magnetic resonance spectroscopy. 3-[2-(N,N-Diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin, 3-cyano-7-ethoxycoumarin (CEC), and dibenzylfluorescein (DBF) were obtained from BD Gentest (Woburn, MA). Vivid BOMCC was purchased from Invitrogen (Carlsbad, CA). ␤-NADP, D-glucose 6-phosphate, glucose-6-phosphate dehydrogenase, and all of the P450 isoformspecific substrates and inhibitors were purchased from Sigma-Aldrich (St. Louis, MO). All other reagents and organic solvents for HPLC were of the highest grade from commercial sources.
Expression of Recombinant Human P450. Full-length cDNAs encoding individual P450 isoforms were subcloned into a galactose-inducible vector, pYES2/CT (Invitrogen), and then transformed into Saccharomyces cerevisiae, whose genome had been modified by integrating the cDNA of human NADPH-cytochrome P450 reductase. The SNP was introduced by site-directed mutagenesis using polymerase chain reaction (Ho et al., 1989) and verified by DNA sequencing. Coexpression of P450 and CPR was started by switching the carbon source in culture media from glucose to galactose. The eight P450 isoforms chosen (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) are major drug-metabolizing P450s responsible for metabolic clearance of most marketed drugs. The nsSNPs we introduced into CYP2C8 and CYP3A4 were those found in populations and published on the web site of the Human P450 Allele Nomenclature Committee (www.cypalleles.ki.se). Both P450 prototypic and variant enzymes were expressed in yeast cells individually and prepared using the same procedure to ensure homogeneous assay conditions for examining the functions of the SNPs.
Microsome Preparation. Yeast microsomes containing recombinant human P450s (rhP450s) and human liver microsomes (HLMs) were prepared by differential centrifugation according to known methods. Liver tissues were provided by Taizhou University's School of Medicine (Taizhou, China) as surgical specimens of human liver. Liver microsomes prepared from 10 individual liver tissues were pooled for use. Microsomal proteins were quantified by Bradford assay (Bradford, 1976; Pearce et al., 1996; Masimirembwa et al., 1999) . The P450 content was measured by CO-reduced difference spectra (Omura and Sato, 1964) . Activities of rhP450 prototypic enzymes were validated by P450 isoform-specific reactions ( Table 1 ). The experimentally obtained Michaelis-Menten constant (K m ) of each reaction was compared with values in the literature for validation of proper P450 activities. The metabolic activities of SNP variants were examined by using fluorogenic substrates (Table 2 ) and compared with those of prototypic enzymes. P450 Reaction Phenotyping. To examine DBZ depletion, individual rhP450 prototypes were incubated with DBZ (3 M) at 37°C for 0, 2, 5, 10, 20, 30, 40, and 60 min in 0.5 ml of 0.1 M phosphate buffer (pH 7.4). The reaction was initiated by adding NADPH-regenerating buffer (␤-NADP at 1.3 mM, D-glucose 6-phosphate and MgCl 2 at 3.3 mM, and glucose-6-phosphate dehydrogenase at 0.4 U/ml) and terminated by adding 0.15 ml of ice-cold acetonitrile. Microsomes prepared from yeast transformed by the null vector (without P450 cDNA) were incubated as a negative control. DBZ was analyzed by HPLC-UV. The percentage of DBZ remaining was plotted versus incubation time to obtain the half-life (t 1/2 ) of DBZ depletion. DBZ clearance was calculated from the t 1/2 value according to known equations (Obach et al., 1997) .
To identify the DBZ metabolites generated by CYP2C8 and CYP3A4, DBZ at 100 M was incubated with 0.5 mg/ml yeast microsomes containing CYP2C8 and CYP3A4, respectively, for 60 min. The incubation of microsomes prepared from yeast transformed by the null vector was used as negative control. HLMs were incubated with DBZ as a positive control. Metabolites of DBZ produced by CYP2C8 or CYP3A4 were analyzed by HPLC-UV. The retention times of metabolite peaks on chromatograms were compared to determine which metabolites were generated by CYP2C8 and CYP3A4.
P450 isoform-specific inhibitors at a concentration of 5-fold more than their inhibition constants (K i s) were incubated with DBZ at 100 M and pooled HLMs at 0.5 mg/ml. Reactions were terminated at a time within the linearity 
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dmd.aspetjournals.org of metabolite formation. The initial rates of metabolite formation were calculated and compared to the control (incubated without inhibitors). The decreased initial rate in the presence of certain P450 isoform-specific inhibitors reflects the involvement of the inhibited P450 isoform in DBZ metabolism. DBZ Metabolism by rhCYP2C8 Variants. The rhCYP2C8 prototypic or variant enzyme was incubated with DBZ at concentrations ranging from 320 to 10 M in 2-fold serial dilutions. The incubation was initiated by adding NADPH-regenerating buffer and terminated by adding ice-cold acetonitrile at a time within the linearity of metabolite formation. The enzyme concentration used was 60 pmol/ml, which was within the linearity of metabolite formation. Metabolites were analyzed by HPLC-UV detection at 280 nm. Formation of the major metabolite generated by CYP2C8 was examined. Its K m and maximum velocity (V max ) values were calculated. The intrinsic clearance (CL int ) was obtained by the ratio of V max /K m . The K m , V max , and CL int values obtained from the experiment were compared with those of the prototypic enzyme by statistical analysis.
P450 Inhibition Assay. Yeast microsomes containing individual rhP450s and fluorogenic probe substrates (Table 2) were used to establish a highthroughput assay for evaluation of the inhibitory potencies of drugs on P450 enzymes as described previously by Crespi and coworkers (Crespi et al., 1997; Crespi and Stresser, 2000) . The half-maximal inhibitory concentration (IC 50 ) of DBZ on the metabolism of a probe substrate mediated by each rhP450 was tested by adding different amounts of DBZ to the reactions. DBZ in 2-fold serial dilutions from 128 to 0.25 M was preincubated with a particular fluorogenic probe in 0.1 ml of 0.1 M phosphate buffer (pH 7.4) in Costar (Corning Life Sciences, Lowell, MA) 96-well black polystyrene plates for 5 min. Reactions were initiated by adding yeast microsomes and terminated by adding different stop buffers at a time within the linearity of product formation. Real-time fluorescence readings were obtained from a SpectraMax GEMINI EM dual-scanning microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA). The percentage of inhibition was plotted against the inhibitor concentration to derive an apparent IC 50 value.
Before the P450 inhibition assays, each rhP450 enzyme was assayed with the corresponding probe substrate to obtain its K m value. The probe substrate at a concentration equivalent to its K m was then used in the inhibition assay, which allowed calculation of the K i of a test compound from the IC 50 value by dividing by two, for a pattern of competitive inhibition (Bjornsson et al., 2003) . The inhibition assays were controlled by P450 isoform-specific inhibitors ( Table 2) . The IC 50 values of these inhibitors were tested in this inhibition assay in the same way as DBZ. The K i values of these inhibitors were calculated and compared with values in the literature for validation of the inhibition assay.
Data Analysis. K m and V max values were determined by the nonlinear regression fitting using Prism, version 4.03 (GraphPad Software, Inc., San Diego, CA). The t 1/2 of DBZ depletion was calculated by regression analysis of semilogarithmic plots, and the IC 50 value was calculated by the linear interpolation using Microsoft Excel (Microsoft, Redmond, WA). Dunnett's test was used for statistical analysis. A p value of Ͻ0.05 was considered statistically significant.
Results

Validations of Yeast-Expressed rhP450 Prototypes and nsSNP Variants.
To validate the catalytic properties of the rhP450s, we examined the enzyme kinetic parameters of P450 isoform-specific reactions and inhibitions using FDA reference probe substrates and procedures (www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm072101. pdf). The K m values of six isoform-specific reactions catalyzed by the yeast-expressed prototypic rhP450 enzymes are summarized in Table 1 . The values of all reactions were comparable to those suggested by the FDA Guidance for Industry: Drug Interaction Studies (www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm072101.pdf). For example, the K m values for the CYP2C8-and CYP3A4-specific reactions were 5.6 Ϯ 0.8 and 6.6 Ϯ 1.0 M, respectively, which are within the reference ranges (5.4 -19 and 5.1-47 M, respectively). These results indicate that the yeast-expressed rhP450s have proper catalytic activities for drug metabolism studies.
For drug inhibition studies, we used these rhP450 enzymes with fluorogenic probes to establish a high-throughput inhibition assay. To validate the assay, P450 isoform-specific inhibitors were used to test their inhibitory potency with the corresponding P450 isoforms. All of the tested specific inhibitors showed strong inhibitory potencies with the corresponding rhP450 isoforms ( Table 2) . The K i values of these inhibitors obtained in our inhibition assays were comparable to those listed in the FDA Guidance for Industry: Drug Interaction Studies (www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072101.pdf). For instance, the K i values of the CYP2C8-and CYP3A4-specific inhibitors (quercetin and ketoconazole, respectively) calculated from our inhibition assay were 1.33 Ϯ 0.08 and 0.011 to 0.015 M, respectively, which agree with the reference values (1.1 and 0.0037-0.18 M, respectively) ( Table  2) . Thus, the inhibition assay we established can be used for assessing the inhibitory potency of a new chemical entity (NCE).
In addition to validation of the prototype enzymes, we compared their activities with those of the rhP450 SNP variants using the same fluorogenic substrates. The activities of 22 P450 SNP variants of the CYP2C8 and CYP3A4 isoforms used in DBZ study are shown in Table 3 . Eleven of these 22 P450 SNP variants demonstrated a tendency toward decreased enzyme activity compared to the prototypic isoforms, whereas the others showed no change. These results correlated well with results in the literature in most cases, even though the results in the literature were reported separately using different assay systems from different laboratories (Table 3 ). These results demonstrate that the rhP450 SNP variants can be used reliably in SNP function studies.
Effects of P450 Nonsynonymous SNPs on DBZ Metabolism. Before investigating the potential effects of P450 nsSNPs on DBZ metabolism, the dominant enzyme responsible for DBZ metabolism should be identified. Our previous work has demonstrated that five 
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org Downloaded from metabolites (labeled M1 to M5) are generated when DBZ is incubated with pooled HLMs (which contain all P450 isoforms), and the most abundant metabolite is M3 . Those data suggested that P450s are most likely to be the major enzymes responsible for DBZ metabolism, but which P450 isoform was the dominant enzyme remained unclear.
To address this question, we used eight individual rhP450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) to examine DBZ depletion. DBZ clearance by rhCYP2C8, rhCYP3A4, and rhCYP3A5 microsomes was approximately 20-fold higher than that by control microsomes prepared from yeast expressing a null vector ( p Ͻ 0.01). Other P450 isoforms had similar DBZ clearances to the control (Fig. 1) . These results suggested that CYP2C8 and CYP3A are involved in DBZ metabolism.
We further analyzed the metabolites generated by rhCYP2C8 and rhCYP3A4 and compared them with those generated by HLMs. Five metabolites, together with M3 (the most abundant), were produced by rhCYP2C8 alone. The retention times of the metabolites matched those produced by HLMs (Fig. 2, a and b) . rhCYP3A4 generated only a single metabolite with a retention time that corresponded to peak M4 produced by HLMs (Fig. 2, a and c) . Moreover, a CYP2C8-specific inhibitor significantly decreased the formation rates of all five metabolites in HLMs, whereas CYP3A-specific inhibitors reduced only M4 formation (Fig. 3 ). These results demonstrate that CYP2C8 is the dominant enzyme responsible for DBZ metabolism and that it generates all five metabolites, including the most abundant one.
Because the CYP2C8 isoform was identified as the dominant enzyme responsible for DBZ metabolism, we evaluated the potential effects of CYP2C8 nsSNPs on DBZ metabolism. Four common CYP2C8 allelic variants, CYP2C8.1, CYP2C8.2, CYP2C8.3, and CYP2C8.4, were examined to determine the kinetic parameters of generation of the major metabolite M3. Among the variants, the DBZ-metabolizing capacity of CYP2C8.3 was significantly lower than that of the CYP2C8 prototype (CYP2C8.1). The CL int of 
The rhCYP2C8 and rhCYP3A4 SNP variants included in our system and their metabolic activities compared with literature values
The CL int s (which reflect the enzyme activity) of the SNP variants were compared with those of the prototypic enzymes (see Supplemental Table S1 ). The activities in parentheses are assumed activities based on the structural alterations or the metabolic ratio of probe substrate.
P450 SNP Variants
Allele Number Activity Table 4) . Although the calculated CL int s of CYP2C8.2 and CYP2C8.4 were 68 and 90%, respectively, of that of CYP2C8.1, the reductions were not significant according to the statistical analysis.
Inhibitory Potency of DBZ: P450 SNP Variants versus Prototypes. Our strategy was to first identify the most DBZ-inhibited P450 isoform and then evaluate the effects of the nsSNPs of the identified isoform on DBZ inhibition. Therefore, we first examined the inhibitory potencies of DBZ for six rhP450 prototypes, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, using fluorogenic probes as substrates. The IC 50 values of DBZ for each rhP450 were calculated and are listed in Table 2 . The inhibition was observed for the isoforms CYP3A4, CYP2C9, and CYP2C19, with IC 50 s of 3.1, 13, and 28 M, respectively. Thus, CYP3A4 is the most DBZinhibited P450 isoform among the six isoforms (Table 2) .
To answer whether the different nsSNPs in the CYP3A4 gene have effects on the inhibitory potency of DBZ, the IC 50 values of DBZ for four CYP3A4 SNP variants that are observed frequently in the population were calculated and compared with that of the prototype. Two structurally unrelated probe substrates, DBF and BOMCC, were used to provide more reliable results. When DBF was used as the probe, the IC 50 values of DBZ for CYP3A4.2 (S222P), 3A4.12 (L373F), and 3A4.16 (T185S) were approximately 10-fold higher than that for the prototypic CYP3A4 enzyme ( p Ͻ 0.01), indicating that the inhibitory potency of DBZ was significantly reduced by these three variants. By contrast, DBZ's inhibitory potency was not influenced by CYP3A4.3 (M445T) and gave an IC 50 for this variant equal to that for the prototypic enzyme (Fig. 4a) . When BOMCC was used as the probe substrate, we observed that the IC 50 value of DBZ for CYP3A4.3, and thus its inhibitory potency toward this variant, was equivalent to that for the prototypic enzyme. The IC 50 value of DBZ for CYP3A4.16 was approximately 9-fold higher ( p Ͻ 0.01), whereas the IC 50 values of DBZ for CYP3A4.2 and CYP3A4.12 were 2-fold higher than that for the CYP3A4 prototypic enzyme (not significant) (Fig. 4b) .
Discussion
To study the in vitro effects of P450 nsSNPs on DBZ metabolism and inhibitory potency, a valid and homogenous assay system is critical. Our yeast-expressed rhP450s have appropriate metabolic activities, because the kinetic parameters of P450 isoform-specific reactions catalyzed by the prototypic enzymes are consistent with the reference data listed in the FDA Guidance (Table 1) . Furthermore, inhibition assays using the yeast-expressed rhP450 prototypic enzymes are valid to examine the inhibitory potencies of drugs to P450 enzymes, because the K i values of P450 isoform-specific inhibitors for P450 prototypic enzymes examined in our system are comparable with the reference data listed in the FDA Guidance ( Table 2 ). The rhP450 SNP variants are also reliable for SNP function studies because, in most cases, the metabolic activities of these SNP variants correlated well with values in the literature (Table 3 ). These results demonstrate that our assay system using prototypic and variant rhP450 enzymes expressed in yeast is valid for drug metabolism and P450 inhibition studies.
For some SNP variants, such as CYP3A4.18 (L293P), our results were different from certain data in the literature. In our system, this variant exhibited normal metabolic activity compared with the CYP3A4 prototype. Our results were thus consistent with data showing that CYP3A4.18 expressed in HepG2 cells had essentially the same metabolic activity toward testosterone 6␤-and 2␤-hydroxylase, as did prototypic CYP3A4 (Murayama et al., 2002) , but were different from those of a study showing that Escherichia coli-expressed CYP3A4.18 had increased metabolic activity toward testosterone and chlorpyrifos (Dai et al., 2001a) . However, in another study, a normal metabolic activity was also reported for E. coli-expressed CYP3A4.18 toward midazolam, testosterone, and nifedipine (Lee et al., 2005; Miyazaki et al., 2008) .
The decreased metabolic activities in our system of two SNP variants, CYP3A4.12 (L373F) and CYP3A4.16 (T185S), were in conflict with results in the literature, which suggested that these variants have normal activity. Note that, in contrast to our study, in which the enzyme parameters were measured directly and the CL int values of the SNP variants were compared with those of the prototypic enzyme, the investigators in the conflicting study merely estimated the enzyme parameters according to protein structural alterations or indirect metabolic ratios of probe substrates. Consistent with our results, decreased activities of these two variants were also reported by other laboratories using rhP450s expressed in other hosts and using other substrates (Eiselt et al., 2001; Murayama et al., 2002; Miyazaki et al., 2008) .
The potential for conflicting results across P450 studies makes it crucial to use a homogeneous assay system for comparing the functions of P450 nsSNPs with the prototypic enzymes and among different nsSNP variants. In the assay system described above, all P450 enzymes are obtained from the same source and the assays are performed using the same probe substrates and the same assay conditions; the only difference is the amino acid substitution in the P450 protein caused by the SNP. This homogeneous system can thus be useful for accurately comparing the influence of P450 nsSNPs on DBZ metabolism and inhibitory potential.
In the DBZ metabolism study, we first identified CYP2C8 as the dominant enzyme responsible for DBZ metabolism. Although the DBZ depletion assay seems to suggest that both CYP2C8 and CYP3A are highly involved in DBZ metabolism (Fig. 1) , the results in Figs. 2   FIG. 3 . Impact on DBZ-metabolite formation rates when HLMs are incubated with P450 isoform-specific inhibitors. The inhibitor concentrations used were 5-fold higher than their K i values: 1 M ␣-naphthoflavone; 10 M quercetin; 5 M sulfaphenazole; 10 M ticlopidine; 5 M quinidine; 1 M ketoconazole; and 50 M verapamil. The control had no inhibitors. Each column presents the mean value Ϯ S.E. obtained from more than three independent experiments. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01.
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org and 3 indicate that only M4 is generated by CYP3A. In HLMs, M4 is less abundant than the other DBZ metabolites , indicating that CYP3A is not the major DBZ-metabolizing enzyme. This result suggests that the significance of CYP3A in Fig. 1 is overestimated. The possible reasons for the overestimation include the following: 1) a higher P450 content in yeast microsomes containing rhCYP3A4 compared to those containing rhCYP2C8, which leads to an apparently similar DBZ clearance when the data are expressed as "microliters per minute per milligram microsomal protein." (When we converted the data to "microliters per minute per picomole P450" by dividing by the P450 content, the DBZ clearance by rhCYP2C8 was approximately twice as high as that by rhCYP3A4.); and 2) the single P450 isoform activity of rhCYP3A4 in the yeast system, which means that any possible substrate-competitive effects of CYP2C8 that occur in HLMs would not be present, resulting in complete and rapid clearance of the small amount of substrate by rhCYP3A4. The higher DBZ-CYP3A4 binding affinity, reflected by the lowest IC 50 value of DBZ to CYP3A4 in the inhibition assay (Table 2) , may also slightly contribute to the calculation of DBZ clearance, even though its significance is limited. When all of the data presented in Figs. 1 to 3 were considered together, we concluded that CYP2C8, instead of CYP3A, is the dominant enzyme responsible for DBZ metabolism.
We further determined that P450 nsSNP CYP2C8.3 results in a significant 54% reduction in DBZ clearance compared with the CYP2C8 prototype (Table 4 ). The effect of this SNP was confirmed in our assay system using BOMCC as substrate, where CYP2C8.3 also showed decreased metabolic activity (Table 3) . These findings of reduced metabolic activity of CYP2C8.3 are consistent with published results using HLMs and bacterially expressed rhCYP2C8s, which showed CYP2C8.3 decreased metabolism of paclitaxel 6␣-hydroxylase (Dai et al., 2001b; Bahadur et al., 2002) . Furthermore, in a separate study using our yeast-expressed CYP2C8.3, a similar decrease in metabolism of paclitaxel 6␣-hydroxylase was also observed (Gao et al., 2010) . Although our results suggest a 54% decrease of DBZ clearance by CYP2C8.3, the differences in the K m and V max values between CYP2C8.3 and the prototypic enzyme are actually not significant (Table 4) , and thus the real importance of this result may be limited. In fact, even though many in vitro studies using recombinant CYP2C8 and HLMs suggested decreased activities of CYP2C8.3, this does not mean that this variant is associated with reduced drug clearance in vivo (Henningsson et al., 2005) , only that it has this potential. Clinical trials will need to be conducted to confirm whether this variant influences DBZ clearance in vivo.
In the inhibition study, we found that compared with CYP3A4 prototype and CYP3A4.3 (M445T), three SNP variants, CYP3A4.2 (S222P), CYP3A4.12, and CYP3A4.16, weakened the inhibitory potency of DBZ. The extent of the effects of the nsSNP variants on inhibition by DBZ were different when two different probe substrates were used, but the tendencies were similar. The difference in the inhibitory degree may reflect the substrate-dependence of inhibition of CYP3A4, as described previously Nomeir et al., 2001) . In addition to the effects of these three CYP3A4 SNP variants on inhibition by drugs, some studies showed that the three variants reduced the metabolism of several CYP3A4 substrates by FIG. 4. Inhibition curves of DBZ on rhCYP3A4 variant enzyme-catalyzed metabolism of fluorogenic probes. a, DBF was used as the probe. IC 50 values for CYP3A4.2, CYP3A4.12, and 3A4.16 (36 Ϯ 6, 46 Ϯ 3, and 54 Ϯ 5 M, respectively) are increased by 9-, 10-, and 12-fold, respectively, compared with that of CYP3A4.1 (4.4 Ϯ 0.4 M) (p Ͻ 0.01). b, BOMCC was used as the probe. The IC 50 value of CYP3A4.16 (27 Ϯ 4 M) is increased by 9-fold compared with that of the CYP3A4 prototype (3.1 Ϯ 0.1 M) (p Ͻ 0.01). Data points represent the means Ϯ S.E. obtained from three independent experiments. The dotted line represents 50% inhibition.
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org increasing K m values (Eiselt et al., 2001; Miyazaki et al., 2008) . These results suggest that the amino acid substitutions in the three variants may affect their affinities for the substrates tested. It is also possible that the substitutions might weaken the affinity of the variants for DBZ, thereby resulting in reduced inhibitory potency as reflected by the increase in IC 50 . As for CYP3A4.3, the amino acid substitution is located near the C terminus, where it may have little influence on the protein structure and metabolic activity (Dai et al., 2001a; Eiselt et al., 2001; Lee et al., 2005) and thus only a minimal effect on the inhibitory potency of DBZ. The effects of P450 nsSNPs on the inhibitory potential of DBZ suggest that individuals who carry the CYP3A4*2, CYP3A4*12, and CYP3A4*16 alleles are less likely to experience CYP3A4-mediated DDIs when DBZ is coadministered, whereas individuals who carry the CYP3A4*3 allele have the same risk as those who carry the prototypic allele. Although these predictions need to be tested and verified in clinical trials, our in vitro results regarding the effects of P450 nsSNPs might help to design clinical trials with respect to P450 genetic polymorphisms.
rhP450s have been widely used in the early stages of drug development to investigate the inhibitory potencies of NCEs. NCEs that exhibit strong inhibitory potencies can then be excluded from downstream procedures (Wienkers and Heath, 2005; Zlokarnik et al., 2005) . In this work, we provide an example of using rhP450s to evaluate the effects of P450 genetic polymorphisms on DDIs in the early stages of drug development. Considering the significance of P450 genotypes on drug safety, to evaluate the possible effects of P450 genetic polymorphisms at early stages of drug development might be of benefit to patients.
In conclusion, we evaluated the effects of P450 nsSNPs on DBZ metabolism and P450-inhibition potential in a valid homogeneous assay system. We found that the metabolic clearance of DBZ was decreased by CYP2C8.3 and that the inhibitory potency of DBZ toward CYP3A4 was weakened by three CYP3A4 allelic variants, which are helpful findings for the safety assessment of DBZ. Our study suggests the use of rhP450 variant enzymes in the early stage of drug screening and development to avoid potential adverse drug reactions caused by P450 nsSNPs.
